Abeona Therapeutics (NASDAQ:ABEO) Downgraded to Sell Rating by StockNews.com

StockNews.com lowered shares of Abeona Therapeutics (NASDAQ:ABEO) from a hold rating to a sell rating in a research report report published on Saturday morning.

Several other brokerages have also issued reports on ABEO. HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $5.78 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock has a 50 day simple moving average of $5.65 and a 200 day simple moving average of $5.82. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The firm has a market capitalization of $251.26 million, a PE ratio of -2.15 and a beta of 1.43.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors have recently bought and sold shares of the company. Twinbeech Capital LP bought a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $58,000. Squarepoint Ops LLC bought a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $67,000. Jane Street Group LLC bought a new stake in Abeona Therapeutics in the 3rd quarter valued at approximately $84,000. Oxford Asset Management LLP bought a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $118,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Abeona Therapeutics in the 3rd quarter valued at approximately $151,000. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.